Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;27(5):287–290. doi: 10.1002/clc.4960270510

Gender‐specific association between preproendothelin‐1 genotype and reduction of systolic blood pressure during antihypertensive treatment‐‐‐results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)

P Hallberg 1,✉, J Karlsson 1, L Lind 1,2, K Michaëlsson 3, L Kurland 1, T Kahan 4, K Malmqvist 4, K P Öhman 4,5, F Nyström 5,6, U Liljedahl 1, A C Syvänen 1, H Melhus 1
PMCID: PMC6654446  PMID: 15188945

Abstract

Background: Studies suggest that endothelin‐1 contributes to the pathogenesis of hypertension. A G5665T gene polymorphism of preproendothelin‐1 has been shown to be associated with higher blood pressure in overweight patients. No study has yet determined the effect of this polymorphism on the change in blood pressure during antihypertensive treatment.

Hypothesis: This study aimed to determine this effect in hypertensive patients with left ventricular (LV) hypertrophy during antihypertensive treatment with either irbesartan or atenolol.

Methods: We determined the preproendothelin‐1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double‐blind fashion to treatment with either the AT1‐receptor antagonist irbesartan or the beta1 ‐adrenoceptor antagonist atenolol.

Results: The change in systolic blood pressure (SBP) after 12 weeks of treatment was related to the preproendothelin‐1 genotype in men; after adjustment for potential covariates (age, blood pressure, and LV mass index at study entry, dose of irbesartan/atenolol, and type of treatment), those carrying the T‐allele responded on average with a more than two‐fold greater reduction than those with the G/G genotype (‐21.9 mmHg [3.9] vs. ‐8.9 [2.3], p = 0.007). No significant differences in blood pressure change between G/G and carriers of the T‐allele were seen among women.

Conclusions: Our finding suggests a gender‐specific relationship between the G5665T preproendothelin‐1 polymorphism and change in SBP in response to antihypertensive treatment with irbesartan or atenolol, suggesting the endothelin pathway to be a common mechanism included in the hypertensive action of the drugs.

Keywords: endothelin, irbesartan, atenolol, hypertension, polymorphism, gender

Full Text

The Full Text of this article is available as a PDF (30.4 KB).

References

  • 1. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T: Anovel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens 1988; 6 (suppl):S 188–191 [DOI] [PubMed] [Google Scholar]
  • 2. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863–2867 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325–415 [PubMed] [Google Scholar]
  • 4. Kozak M, Izakovicova H, Krivan L, Vasku A, Sepsi M, Borivoj S, Vacha J: Endothelin‐1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia. Med Sci Monit 2002; 8:BR164–167 [PubMed] [Google Scholar]
  • 5. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP: Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) 1996; 90: 37–46 [DOI] [PubMed] [Google Scholar]
  • 6. Serneri GG, Modesti PA, Boddi M, Cecioni I, Paniccia R, Coppo M, Galanti G, Simonetti I, Vanni S, Papa L, Bandinelli B, Migliorini A, Modesti A, Maccherini M, Sani G, Toscano M: Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 1999; 85: 57–67 [DOI] [PubMed] [Google Scholar]
  • 7. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Davenport AP: Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 1993; 72: 526–538 [DOI] [PubMed] [Google Scholar]
  • 8. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, Ogura M, Inoue A, Marumo F: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15: 493–496 [DOI] [PubMed] [Google Scholar]
  • 9. Schiffrin EL, Deng LY, Sventek P, Day R: Enhanced expression of endothelin‐1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15: 57–63 [DOI] [PubMed] [Google Scholar]
  • 10. Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, Hosoda K, Nakao K, Sasayama S: Endothelin‐ 1‐selective receptor in the arterial intima of patients with hypertension. Hypertension 1994; 23: 288–293 [DOI] [PubMed] [Google Scholar]
  • 11. Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V: The effect of an endothelin‐receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338: 784–790 [DOI] [PubMed] [Google Scholar]
  • 12. Iglarz M, Benessiano J, Philip I, Vuillaumier‐Barrot S, Lasocki S, Hvass U, Durand G, Desmonts JM, Levy BI, Henrion D: Preproendothelin‐1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 2002; 39: 209–213 [DOI] [PubMed] [Google Scholar]
  • 13. Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJ, Dargie HJ, Arveiler D, Ruidavets JB, Luc G, Evans A, Cambien F: The Lys 198 Asn polymorphism in the endothelin‐1 gene is associated with blood pressure in overweight people. Hypertension 1999; 33: 1169–1174 [DOI] [PubMed] [Google Scholar]
  • 14. Barden AE, Herbison CE, Beilin LJ, Michael CA, Walters BN, Van Bockxmeer FM: Association between the endothelin‐1 gene Lys 198Asn polymorphism blood pressure and plasma endothelin‐1 levels in normal and pre‐eclamptic pregnancy. J Hypertens 2001; 19: 1775–1782 [DOI] [PubMed] [Google Scholar]
  • 15. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller‐Brunotte R, Nystrom F, Ohman KP, Osbakken MD, Ostergern J: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–1176 [DOI] [PubMed] [Google Scholar]
  • 16. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H: The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) trial. J Hypertens 2002; 20: 2089–2093 [DOI] [PubMed] [Google Scholar]
  • 17. Syvanen AC, Sajantila A, Lukka M: Identification of individuals by analysis of biallelic DNA markers, using PCR and solid‐phase minisequencing. Am J Hum Genet 1993; 52: 46–59 [PMC free article] [PubMed] [Google Scholar]
  • 18. Lamping KG, Nuno DW: Effects of 17 beta‐estradiol on coronary microvascular responses to endothelin‐1. Am J Physiol 1996; 271: H1117–1124 [DOI] [PubMed] [Google Scholar]
  • 19. Sudhir K, Ko E, Zellner C, Wong HE, Hutchison SJ, Chou TM, Chatterjee K: Physiological concentrations of estradiol attenuate endothelin 1‐induced coronary vasoconstriction in vivo. Circulation 1997; 96: 3626–3632 [DOI] [PubMed] [Google Scholar]
  • 20. Polderman KH, Stehouwer CD, van Kamp GJ, Schalkwijk CG, Gooren LJ: Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000; 49: 648–650 [DOI] [PubMed] [Google Scholar]
  • 21. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ: Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429–432 [DOI] [PubMed] [Google Scholar]
  • 22. Best PJ, Berger PB, Miller VM, Lerman A: The effect of estrogen replacement therapy on plasma nitric oxide and endothelin‐1 levels in postmenopausal women. Ann Intern Med 1998; 128: 285–288 [DOI] [PubMed] [Google Scholar]
  • 23. Wang X, Barber DA, Lewis DA, McGregor CG, Sieck GC, Fitzpatrick LA, Miller VM: Gender and transcriptional regulation of NO synthase and ET‐1 in porcine aortic endothelial cells. Am J Physiol 1997; 273: H1962–1967 [DOI] [PubMed] [Google Scholar]
  • 24. Ylikorkala O, Orpana A, Puolakka J, Pyorala T, Viinikka L: Postmenopausal hormonal replacement decreases plasma levels of endothelin‐1. J Clin Endocrinol Metab 1995; 80: 3384–3387 [DOI] [PubMed] [Google Scholar]
  • 25. David FL, Carvalho MH, Cobra AL, Nigro D, Fortes ZB, Reboucas NA, Tostes RC: Ovarian hormones modulate endothelin‐1 vascular reactivity and mRNA expression in DOCA‐salt hypertensive rats. Hypertension 2001; 38: 692–696 [DOI] [PubMed] [Google Scholar]
  • 26. Ergul A, Shoemaker K, Puett D, Tackett RL: Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther 1998; 285: 511–517 [PubMed] [Google Scholar]
  • 27. Kellogg DL Jr, Liu Y, Pergola PE: Selected contribution: Gender differences in the endothelin‐B receptor contribution to basal cutaneous vascular tone in humans. J Appl Physiol 2001; 91: 2407–2411; discussion 2389–2390 [DOI] [PubMed] [Google Scholar]
  • 28. Tatchum‐Talom R, Martel C, Labrie C, Labrie F, Marette A: Gender differences in hemodynamic responses to endothelin‐1. J Cardiovasc Pharmacol 2000; 36: S102–104 [DOI] [PubMed] [Google Scholar]
  • 29. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Hagg A, Lind L: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783–1787 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES